CCL22 and IL-37 inhibit the proliferation and epithelial-mesenchymal transition process of NSCLC A549 cells Corrigendum in /10.3892/or.2020.7903

Chen,Yu-Hua; Zhou,Bi-Yun; Wu,Xian-Jing; Xu,Jun-Fa; Zhang,Jun‑Ai; Chen,Yong-Hua; Liang,Si-Si

doi:10.3892/or.2016.4995

CCL22 and IL-37 inhibit the proliferation and epithelial-mesenchymal transition process of NSCLC A549 cells

Corrigendum in: /10.3892/or.2020.7903

Authors:
- Yu-Hua Chen
- Bi-Yun Zhou
- Xian-Jing Wu
- Jun-Fa Xu
- Jun‑Ai Zhang
- Yong-Hua Chen
- Si-Si Liang
View Affiliations

Affiliations: Department of Clinical Laboratory, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, P.R. China, Department of Interventional Ward, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, P.R. China, Department of Clinical Immunology, Institute of Laboratory Medicine, Guangdong Medical College, Dongguan 523808, P.R. China, Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Dongguan 523808, P.R. China, Department of Pathology, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, P.R. China, Department of Orthopedics, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524001, P.R. China
Published online on: August 2, 2016 https://doi.org/10.3892/or.2016.4995
Pages: 2017-2024

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, we aimed to investigate the effects of CC chemokine ligand 22 (CCL22) and interleukin-37 (IL-37) on the proliferation and epithelial-mesenchymal transition (EMT) of non-small cell lung cancer (NSCLC) A549 cells. pDsRed-CCL22 and pEGFP-IL-37 plasmids were constructed. A549 cells were divided into six groups: the control, the pDsRed-N1 blank plasmid, the pEGFP-C1 blank plasmid, the pDsRed-CCL22 plasmid, the pEGFP‑IL-37 plasmid and the pDsRed-CCL22 + pEGFP-IL-37 plasmid group. Expression levels and localization of CCL22 and IL-37 in cells were detected by confocal microscopy. Phase-contrast microscopy was applied for observing cellular morphology. Real-time fluorescence quantitative polymerase chain reaction (RT-qPCR) was used for detecting the mRNA levels of vimentin, N-cadherin and E-cadherin, and their protein expression levels were tested using western blotting. Constructed plasmids expressed CCL22 and IL-37, both of which had a co-localization in the cell membrane. MTT assay and cell observation results revealed that CCL22 and IL-37 inhibited the proliferation and EMT process of the A549 cells. The results of RT-qPCR and western blotting revealed that decreased vimentin and N-cadherin mRNA and protein expression levels, and increased E-cadherin mRNA and protein expression levels were found in the pDsRed-CCL22 plasmid, pEGFP-IL-37 plasmid and pDsRed‑CCL22 + pEGFP‑IL-37 plasmid groups when compared with the control, the pDsRed-N1 blank plasmid and the pEGFP-C1 blank plasmid groups (all P<0.05), and decreased vimentin and N-cadherin mRNA and protein expression levels and increased E-cadherin mRNA and protein expression levels were found in the pDsRed‑CCL22 + pEGFP‑IL-37 plasmid group when compared with the pDsRed-CCL22 plasmid and the pEGFP‑IL-37 plasmid groups (all P<0.05). CCL22 and IL-37 with a co-localization in the A549 cells inhibited the proliferation and EMT process in A549 cells. The antitumor effects of CCL22 and IL37 provide a strategy for the treatment of NSCLC.

View Figures

View References

1	Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks JD; National Lung Screening Trial Research Team: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
2	Wu H, Qiao N, Wang Y, Jiang M, Wang S, Wang C and Hu L: Association between the telomerase reverse transcriptase (TERT) rs2736098 polymorphism and cancer risk: Evidence from a case-control study of non-small-cell lung cancer and a meta-analysis. PLoS One. 8:e763722013. View Article : Google Scholar : PubMed/NCBI
3	Xu J, Yin Z, Gao W, Liu L, Yin Y, Liu P and Shu Y: Genetic variation in a microRNA-502 minding site in SET8 gene confers clinical outcome of non-small cell lung cancer in a Chinese population. PLoS One. 8:e770242013. View Article : Google Scholar : PubMed/NCBI
4	Liu XH, Liu ZL, Sun M, Liu J, Wang ZX and De W: The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer. BMC Cancer. 13:4642013. View Article : Google Scholar : PubMed/NCBI
5	Pao W and Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011. View Article : Google Scholar : PubMed/NCBI
6	Dela Cruz CS, Tanoue LT and Matthay RA: Lung cancer: Epidemiology, etiology, and prevention. Clin Chest Med. 32:605–644. 2011. View Article : Google Scholar : PubMed/NCBI
7	Raz DJ, Gomez SL, Chang ET, Kim JY, Keegan TH, Pham J, Kukreja J, Hiatt RA and Jablons DM: Epidemiology of non-small cell lung cancer in Asian Americans: Incidence patterns among six subgroups by nativity. J Thorac Oncol. 3:1391–1397. 2008. View Article : Google Scholar : PubMed/NCBI
8	Albain KS, Swann RS, Rusch VW, Turrisi AT III, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, et al: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet. 374:379–386. 2009. View Article : Google Scholar : PubMed/NCBI
9	Kitano H, Chung JY, Ylaya K, Conway C, Takikita M, Fukuoka J, Doki Y, Hanaoka J and Hewitt SM: Profiling of phospho-AKT, phospho-mTOR, phospho-MAPK and EGFR in non-small cell lung cancer. J Histochem Cytochem. 62:335–346. 2014. View Article : Google Scholar : PubMed/NCBI
10	Lee SH, Suh IB, Lee EJ, Hur GY, Lee SY, Lee SY, Shin C, Shim JJ, In KH, Kang KH, et al: Relationships of coagulation factor XIII activity with cell-type and stage of non-small cell lung cancer. Yonsei Med J. 54:1394–1399. 2013. View Article : Google Scholar : PubMed/NCBI
11	Song G, Qin T, Liu H, Xu GB, Pan YY, Xiong FX, Gu KS, Sun GP and Chen ZD: Quantitative breath analysis of volatile organic compounds of lung cancer patients. Lung Cancer. 67:227–231. 2010. View Article : Google Scholar
12	Ma H, Shu Y, Pan S, Chen J, Dai J, Jin G, Hu Z and Shen H: Polymorphisms of key chemokine genes and survival of non-small cell lung cancer in Chinese. Lung Cancer. 74:164–169. 2011. View Article : Google Scholar : PubMed/NCBI
13	Singh S, Sadanandam A and Singh RK: Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev. 26:453–467. 2007. View Article : Google Scholar : PubMed/NCBI
14	Niens M, Visser L, Nolte IM, van der Steege G, Diepstra A, Cordano P, Jarrett RF, Te Meerman GJ, Poppema S and van den Berg A: Serum chemokine levels in Hodgkin lymphoma patients: Highly increased levels of CCL17 and CCL22. Br J Haematol. 140:527–536. 2008. View Article : Google Scholar : PubMed/NCBI
15	Freier CP, Kuhn C, Rapp M, Endres S, Mayr D, Friese K, Anz D and Jeschke U: Expression of CCL22 and infiltration by regulatory T cells are increased in the decidua of human miscarriage placentas. Am J Reprod Immunol. 74:216–227. 2015. View Article : Google Scholar : PubMed/NCBI
16	Tete S, Tripodi D, Rosati M, Conti F, Maccauro G, Saggini A, Cianchetti E, Caraffa A, Antinolfi P, Toniato E, et al: IL-37 (IL-1F7) the newest anti-inflammatory cytokine which suppresses immune responses and inflammation. Int J Immunopathol Pharmacol. 25:31–38. 2012.PubMed/NCBI
17	Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P and Dinarello CA: IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 11:1014–1022. 2010. View Article : Google Scholar : PubMed/NCBI
18	Xu D, Wang A, Jiang F, Hu J and Zhang X: Effects of interleukin-37 on cardiac function after myocardial infarction in mice. Int J Clin Exp Pathol. 8:5247–5251. 2015.PubMed/NCBI
19	Xia L, Shen H and Lu J: Elevated serum and synovial fluid levels of interleukin-37 in patients with rheumatoid arthritis: Attenuated the production of inflammatory cytokines. Cytokine. 76:553–557. 2015. View Article : Google Scholar : PubMed/NCBI
20	Wang G, Yu D, Tan W, Zhao D, Wu C and Lin D: Genetic polymorphism in chemokine CCL22 and susceptibility to Helicobacter pylori infection-related gastric carcinoma. Cancer. 115:2430–2437. 2009. View Article : Google Scholar : PubMed/NCBI
21	Erfani N, Nedaei Ahmadi AS, Ghayumi MA and Mojtahedi Z: Genetic polymorphisms of CCL22 and CCR4 in patients with lung cancer. Iran J Med Sci. 39:367–373. 2014.PubMed/NCBI
22	Dougan M, Li D, Neuberg D, Mihm M, Googe P, Wong KK and Dranoff G: A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J Clin Invest. 121:2436–2446. 2011. View Article : Google Scholar : PubMed/NCBI
23	Jin Y, Xiong X, Su Y, Hu J and Tao X: Serum vascular endothelial growth factor levels in patients with non-small cell lung cancer and its relations to the micrometastasis in peripheral blood. J Huazhong Univ Sci Technolog Med Sci. 29:462–465. 2009. View Article : Google Scholar : PubMed/NCBI
24	Thelen M and Stein JV: How chemokines invite leukocytes to dance. Nat Immunol. 9:953–959. 2008. View Article : Google Scholar : PubMed/NCBI
25	Speyer CL and Ward PA: Role of endothelial chemokines and their receptors during inflammation. J Invest Surg. 24:18–27. 2011. View Article : Google Scholar : PubMed/NCBI
26	Xia S, Wei J, Wang J, Sun H, Zheng W, Li Y, Sun Y, Zhao H, Zhang S, Wen T, et al: A requirement of dendritic cell-derived interleukin-27 for the tumor infiltration of regulatory T cells. J Leukoc Biol. 95:733–742. 2014. View Article : Google Scholar
27	Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, Mangelberger D, Oostingh GJ, Pfaller T, Pixner C, Posselt G, et al: IL-37: A new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw. 22:127–147. 2011.PubMed/NCBI
28	Ma P, Gu B, Xiong W, Tan B, Geng W, Li J and Liu H: Glimepiride promotes osteogenic differentiation in rat osteoblasts via the PI3K/Akt/eNOS pathway in a high glucose microenvironment. PLoS One. 9:e1122432014. View Article : Google Scholar : PubMed/NCBI
29	Maloy KJ and Powrie F: Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 474:298–306. 2011. View Article : Google Scholar : PubMed/NCBI
30	Lindsey S and Langhans SA: Crosstalk of oncogenic signaling pathways during epithelial-mesenchymal transition. Front Oncol. 4:3582014. View Article : Google Scholar
31	Nagathihalli NS and Merchant NB: Src-mediated regulation of E-cadherin and EMT in pancreatic cancer. Front Biosci. 17:2059–2069. 2012. View Article : Google Scholar
32	Li MX and Liu BC: Epithelial to mesenchymal transition in the progression of tubulointerstitial fibrosis. Chin Med J. 120:1925–1930. 2007.PubMed/NCBI